A5071698804- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Heparin-Induced Thrombocytopenia and Thrombosis
- Intramuscular injections and effects
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Retinoids in leukemia and cellular processes
- Glioma Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
- Hematological disorders and diagnostics
- Blood groups and transfusion
- Protein Degradation and Inhibitors
- Cutaneous lymphoproliferative disorders research
- Eosinophilic Disorders and Syndromes
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Childhood Cancer Survivors' Quality of Life
- Venomous Animal Envenomation and Studies
- Mesenchymal stem cell research
Ramathibodi Hospital
2010-2024
Mahidol University
2011-2024
University of Pittsburgh
2012
Extranodal NK/T-cell lymphoma (ENKTL), nasal type, may be of NK or T-cell origin; however, the proportion T-ENKTLs and whether they are αβ γδ type remains uncertain. To elucidate cell origin detailed phenotype ENKTL assess any clinicopathologic associations, 67 cases from Thailand were investigated, together with 5 enteropathy-associated lymphomas (EATLs) for comparison. In all, 70% receptor (TCR) β,γ and, in tested, δ negative (presumptive origin); 5% TCR γδ+, 3% αβ+, 1% αβ/γδ+, 21%...
Standard treatment with a thiotepa-based regimen in countries limited resource is less feasible. Aims of the study were to evaluate outcome, and identify prognostic factors patients primary central nervous system lymphoma (PCNSL). We conducted retrospective 43 diagnosed PCNSL, DLBCL subtype, who treated either HDMTX-based regimen, whole brain radiotherapy (WBRT), or both between 2010 2017. There median age 65 years (range 34–89 years). Protein expression CD10, Bcl6, MUM1, Bcl2 MYC found 19,...
Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results thalidomide non-transplant MM patients. We therefore conducted retrospective study 42 consecutive patients with newly diagnosed relapsed/refractory treated thalidomide- induction regimens followed by maintenance therapy.Induction dexamethasone, oral combination melphalan, prednisolone administrated 22 16 respectively....
Cytogenetic abnormalities and mutated genes indicate the role of consolidation therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute myeloid leukemia (AML). In this study, we conducted a retrospective study adult AML patients newly diagnosed de novo who did not undergo HSCT, to long term relapse free survival (RFS) overall (OS) after chemotherapy.We recruited 141 consecutive during January 2010-June 2017, received induction standard dose Ara-C Idarubicin (7 + 3...
Recently, peripheral blood stem cell (PBSC) has been widely used and replaced bone marrow (BM) as the source in allogeneic hematopoietic transplantation (HSCT) because of a more rapid engraftment, easier accessibility, lower risk donor complications. We, therefore, report predicting factors for high PBSC harvest yields 50 healthy donors. Among donors, median collected CD34 + number was 4.6 × 10 6/ kg (1.5–16.3 6 /kg). Number circulating CD34+ cells hematocrit (HCT) level increased parallelly...
IntroductionVaccine‐induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector coronavirus disease 2019 (COVID‐19) vaccine ChAdOx1 nCoV‐19 in European countries. To date, two cases of VITT have Thais COVID‐19 vaccination. We determined frequency anti–platelet factor 4 (PF4)/polyanionic antibodies Thai population receiving vaccines.MethodsWe conducted a cross‐sectional study to evaluate prevalence anti‐PF4/polyanionic health care workers who...
Methotrexate-related lymphoproliferative disorders (MTX-LPDs) are immunodeficiency diseases following methotrexate (MTX) administration, mainly occurring in rheumatoid arthritis patients. Although uncommon, MTX-LPDs have been reported some patients with psoriasis, dermatomyositis, and cutaneous T-cell lymphoma (CTCL) who received MTX. Granulomatous mycosis fungoides (GMF) is a rare subtype of lymphoma, where MTX one the treatment options recalcitrant cases. Herein, we report case 72-year-old...
Abstract Background MYC/BCL2 double expression (DE) is associated with poor prognosis in patients diffuse large B-cell lymphoma (DLBCL) receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). This study aimed to determine whether the addition of DE National Comprehensive Cancer Network Internal Prognostic Index (NCCN-IPI) could improve prediction disease progression DLBCL treated R-CHOP. Methods confirmatory prognostic factor retrospectively recruited...
Abstract Background The prevalence of anti-platelet factor 4 (PF4)/polyanionic antibodies occurring after vaccination with ChAdOx1 nCoV-19 is low. Most these are not associated vaccine-induced thrombotic thrombocytopenia. It remains unknown whether preexisting or occur as a result vaccination. In this study, we demonstrated the incidence anti-PF4/polyanionic antibodies, thrombocytopenia, and thrombosis in large cohort Thais. Methods We conducted prospective study health care workers members...
Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituximab cyclophosphamide doxorubicin vincristine and prednisone (R-CHOP). About 50–70% patients may be cured by R-CHOP. There was no data on external validation comparison international prognostic index, revised-IPI (R-IPI), enhanced-IPI (NCCN-IPI) to predict treatment outcomes in middle-income country with a resourced-limited setting.Objectives We...
Acute myeloid leukemia (AML) is a common, challenging hematologic malignancy worldwide. Thai data on its characteristics and outcomes have never been systematically reported, to our knowledge. The objective of this study was determine the clinical features patients with AML.This prospective observational nine academic hospitals. Patients newly diagnosed AML were invited register online.A total 679 included. presence circulating peripheral blood blasts correlated high white cell count....
Multiple myeloma (MM) accounts for 10% of hematologic malignancies. However, most the patients suffered from relapsed/refractory disease. We would like to expand CAR T cell therapy treat MM using our current platform.
"AML with MECOM rearrangement" was recently categorized by WHO classification 2022 regardless of blast count, which included those present MDS and AML into this group. We aim to explore frequency, clinical characteristics, outcomes in subtype among Thai myeloid neoplasms. data collected from a multicenter study rearrangements were analyzed compared other subtypes. A total 15 cases rearrangement detected, 5/166 (3%) while 10/1082 (0.9%) AML. Eleven (73%) female. showed lower hemoglobin, but...
Multiple myeloma (MM) patients considered to be at high cytogenetic risk commonly fail respond standard treatment. A thorough understanding of the molecular mechanism MM development is, therefore, needed. We endeavored explore transcriptional signature among different subgroups newly diagnosed using gene chip-based expression microarray. Bone marrow samples 15 Thai were included. The chromosomal translocation t(4;14) was most frequently identified genetic alteration in high-risk subgroup....
Abstract Introduction Vaccine-induced thrombotic thrombocytopenia (VITT) has been reported after vaccination with the adenoviral vector COVID-19 vaccine ChAdOx1 nCoV-19 in European countries. To date, no case of VITT Thais vaccination. We determined frequency anti-PF4/polyanionic antibodies Thai population receiving vaccines. Methods conducted a cross-sectional study to evaluate prevalence health care workers who received or CoronaVac within 7-35 days. A control had not vaccinated was also...